FDAsafety guidance72% confidence
Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Bayer.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Various · Pharmaceuticals
- Sub-indication
- General
Related signal: Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity